Capricorn Fund Managers Ltd Acquires New Shares in Maravai LifeSciences Holdings, Inc. $MRVI

Capricorn Fund Managers Ltd bought a new position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 339,727 shares of the company’s stock, valued at approximately $961,000. Capricorn Fund Managers Ltd owned approximately 0.13% of Maravai LifeSciences at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Barclays PLC lifted its position in shares of Maravai LifeSciences by 3.0% in the 4th quarter. Barclays PLC now owns 172,281 shares of the company’s stock worth $560,000 after purchasing an additional 5,057 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Maravai LifeSciences by 12.5% during the second quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock valued at $112,000 after buying an additional 5,160 shares during the period. Epacria Capital Partners LLC raised its stake in Maravai LifeSciences by 6.8% in the third quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock worth $287,000 after buying an additional 6,384 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Maravai LifeSciences by 121.1% in the second quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock worth $43,000 after buying an additional 9,870 shares in the last quarter. Finally, Sprott Inc. purchased a new stake in Maravai LifeSciences during the third quarter worth $29,000. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Insiders Place Their Bets

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the transaction, the general counsel directly owned 360,767 shares of the company’s stock, valued at $1,825,481.02. This represents a 6.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.49% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have issued reports on MRVI shares. Wells Fargo & Company increased their target price on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research report on Friday, May 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $6.00 price objective on shares of Maravai LifeSciences in a research note on Friday, May 8th. UBS Group reaffirmed a “reduce” rating on shares of Maravai LifeSciences in a research report on Wednesday, June 3rd. Weiss Ratings upgraded Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Finally, Wall Street Zen upgraded shares of Maravai LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, Maravai LifeSciences presently has an average rating of “Hold” and a consensus target price of $5.50.

Maravai LifeSciences Price Performance

Shares of MRVI opened at $6.24 on Wednesday. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -8.79 and a beta of 0.72. Maravai LifeSciences Holdings, Inc. has a twelve month low of $1.99 and a twelve month high of $6.55. The company has a quick ratio of 4.96, a current ratio of 5.91 and a debt-to-equity ratio of 0.72. The company has a 50 day moving average of $4.64 and a two-hundred day moving average of $3.81.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The business had revenue of $65.84 million for the quarter, compared to the consensus estimate of $53.00 million. As a group, analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.2 earnings per share for the current fiscal year.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.